Can antiviral drugs turn the tide on COVID-19?

In this episode, we discuss how the novel COVID-19 oral antivirals work and answer questions about them from readers.

There have been claims that COVID-19 oral antivirals, such as molnupiravir and Paxlovid (nirmatrelvir + ritonavir; Pfizer), will “change the course of the pandemic”. But with limited supply, a short treatment window and only a few patient groups eligible to receive them — can these drugs really turn things around?

In this episode of The PJ Pod, Dawn Connelly, features editor, and Julia Robinson, clinical and science editor, look at how these novel drugs work and answer questions from PJ readers on how they will be used in practice.

To explain all this, our editors are joined by Penny Ward, visiting professor in pharmaceutical medicine at King’s College London, and Fiona Marra, a consultant infectious disease pharmacist based in Scotland, who has a central role in deploying the COVID-19 antivirals.

Thank you to Rob Ardley, Nicola Vasey, Umeh Ali and Gareth Malson for their questions. This episode was produced by Geoff Marsh.

Want to hear more from The PJ Pod? Follow us on SpotifyGoogle PodcastsApple Podcasts or Soundcloud to download our latest podcasts.

Last updated
The Pharmaceutical Journal, PJ, February 2022, Vol 308, No 7958;308(7958)::DOI:10.1211/PJ.2022.1.126991

    Please leave a comment 

    You may also be interested in